By Assoc. Prof. Dr. Mehmet Sorar | Published: 08.02.2025
Deep Brain Stimulation (DBS): A Modern Surgical Treatment Method for Movement Disorders
Deep brain stimulation (DBS) delivers continuous electrical pulses to deep brain areas through implanted electrodes and a generator in the chest. It is used for several conditions, but the strength of the evidence differs. Parkinson’s disease has randomised trials, essential tremor rests mainly on literature reviews, and epilepsy has a US Food and Drug Administration (FDA) record in which the main trial result was not statistically significant. This page shows how to read the evidence for each.
Which conditions is DBS used for, and where does each stand?
Cleveland Clinic lists dystonia, essential tremor, medication-resistant epilepsy, Parkinson’s disease and medication-resistant obsessive-compulsive disorder (OCD) as FDA-approved conditions. The same page says researchers do not fully know how DBS works. The records behind each condition differ, as the table shows.
| Condition | Official record | Evidence |
|---|---|---|
| Parkinson’s disease | An FDA summary lists bilateral stimulation (on both sides of the brain) of the globus pallidus internus or subthalamic nucleus as an add-on in advanced disease that responds to levodopa, the most widely used Parkinson’s medicine. | Randomised trials and the 2018 review by the International Parkinson and Movement Disorder Society (MDS). |
| Essential tremor | The same FDA summary dates the system’s first approval, for upper-limb tremor from essential or parkinsonian tremor, to 1997. | A 2019 literature review, not a randomised comparison, and higher figures from a patient foundation. |
| Epilepsy | FDA approval on 27 April 2018 for adults with partial-onset seizures (starting in one part of the brain) resistant to three or more medicines. | One randomised trial and long open-label follow-up. |
| OCD | Listed as FDA-approved for medication-resistant OCD by Cleveland Clinic. | Not reviewed on this page. Ask for the trial data behind any offer. |
| Dystonia | Listed as FDA-approved by Cleveland Clinic. | Set out in dystonia treatment with DBS and botulinum toxin. |
Why can’t one number describe DBS?
Because the studies ask different questions of different people. Before trusting a figure, check who was enrolled, how long they were followed, what they were compared with and what was measured. The measure alone changes the meaning of “improvement”:
- In the 2009 Parkinson’s trial, it is hours of “on” time (when medicine is working) without troubling dyskinesia (involuntary jerky movements) and the share of people with a clinically meaningful motor improvement.
- For essential tremor, it is a percentage fall in tremor.
- For epilepsy, it is the percentage change in seizure frequency.
These cannot be set side by side to say DBS works better in one condition than another.
What does the evidence show in Parkinson’s disease?
The 2009 trial by Weaver and colleagues enrolled 255 people with Parkinson’s disease. DBS added a mean 4.6 hours a day of “on” time without troubling dyskinesia, against none with medical therapy alone, and 71% reached a clinically meaningful motor improvement against 32% with medicine, over six months. At least one serious adverse event occurred in 49 DBS patients and 15 medicine patients, and one person died of bleeding in the brain.
The 2018 MDS evidence review rated bilateral subthalamic and bilateral pallidal DBS as clinically useful for motor fluctuations (times when medicine wears off) and dyskinesia. It found no clinically useful intervention to prevent or delay progression, so DBS cannot be said to slow Parkinson’s. Trial details are in DBS in Parkinson’s disease.
What is known about DBS in essential tremor?
For essential tremor, the International Essential Tremor Foundation says the electrode goes into the ventral intermediate nucleus of the thalamus and that DBS reduces tremor but is not a cure. A 2019 literature review in the Journal of Neurology, Neurosurgery and Psychiatry reports a one-year tremor reduction of 53 to 63% with stimulation on one side and 66 to 78% on both sides, with several studies showing benefit for up to five years. The foundation quotes higher figures, about 90% improvement in hand tremor and about 85% in function and daily activities in most studies, kept for at least 7 to 10 years in most people, though the benefit may fade. These are its own summary figures, not figures from a named trial, so read them with caution.
The foundation says the most serious problems (infection, bleeding inside the brain, seizures) occur in fewer than 5% of people and that rare complications can be fatal. DBS on both sides may cause speech and language problems, and hardware problems such as infection, skin erosion or malfunction may need more surgery. The 2019 review found tingling, slurred speech and unsteadiness common, more so with stimulation on both sides, and many of these were temporary. The condition itself is explained in what essential tremor is.
What does an official approval mean for epilepsy?
An approval is not the same as strong evidence. The FDA summary for epilepsy describes bilateral stimulation of the anterior nucleus of the thalamus as an add-on for adults with partial-onset seizures that resist three or more medicines. It was shown in people averaging six or more seizures a month and was not evaluated in people with fewer.
In the blinded phase of about 3 months, when participants did not know whether stimulation was on, 109 people were randomised (54 active, 55 control). The planned analysis showed 8% fewer seizures with stimulation (the likely range ran from 29.2% fewer to 20.0% more), which was not statistically significant. Only after removing one outlier did a later (post-hoc) analysis show 17% fewer seizures, and none of the secondary outcomes differed significantly. The FDA approved the system after 7 years of open-label follow-up, without a control group. Of 110 implanted people, 8 (7.3%) had bleeding inside the skull and 12 (10.9%) a serious implant-site infection, with 9 (8.2%) needing partial or complete system removal. In the blinded phase, depression was reported by 14.8% of the active group against 1.8% of controls, and memory impairment by 13.0% against 1.8%.
Which uses are still experimental, and what limits DBS?
Cleveland Clinic lists addiction, Alzheimer’s disease, anxiety, cluster headache, eating disorders, schizophrenia, severe pain, severe depression and Tourette syndrome as under research, meaning benefit is not confirmed. The FDA epilepsy summary lists diathermy (heat therapy), certain MRI configurations and transcranial magnetic stimulation as contraindicated (not to be used) with an implanted system, and it also lists people who are unable to operate the patient programmer.
With an implant in place, sudden weakness, a new seizure or sudden trouble speaking is an emergency, because Cleveland Clinic lists bleeding and stroke among the risks. Call emergency services (112 in Türkiye) instead of waiting for a clinic visit, and ring the surgical team the same day about fever or a red or leaking wound. The FDA records describe DBS as an add-on in Parkinson’s and epilepsy, so do not stop or change your medicines on your own. The warning signs and device questions are in life after Parkinson’s surgery. The basics of the device are in what deep brain stimulation is.
Sources
- Cleveland Clinic: Deep brain stimulation (DBS), 2022
- International Essential Tremor Foundation: Deep brain stimulation
- FDA: Summary of safety and effectiveness data, Medtronic DBS system for epilepsy (2018)
- JAMA: Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease, a randomized controlled trial (2009)
- Movement Disorders: MDS evidence-based medicine review, treatments for the motor symptoms of Parkinson’s disease (2018)
- Journal of Neurology, Neurosurgery and Psychiatry: Outcomes from stereotactic surgery for essential tremor (2019)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: Parkinson